A genetic approach to cancer epigenetics

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 335-341

  Feinberg, A P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; GROWTH FACTOR;

APC GENE; BECKWITH WIEDEMANN SYNDROME; CANCER GENETICS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC EPIGENESIS; GENOME IMPRINTING; HUMAN; IGF2 GENE; KIDNEY CELL; KVLQT1 GENE; LIT1 GENE; METHYLATION; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; STEM CELL; ARTICLE; CANCER GROWTH; CHROMATIN; COLON ADENOMA; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; HISTOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; TUMOR CELL; UNIPARENTAL DISOMY;

ANIMALS; BECKWITH-WIEDEMANN SYNDROME; COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; GENOMIC IMPRINTING; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KIDNEY NEOPLASMS; MICE; MODELS, GENETIC; MUTATION; NEOPLASMS; RNA, UNTRANSLATED; WILMS TUMOR;

ANIMALIA;

EID: 33746468496     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.027     Document Type: Conference Paper

References (55)

1. Akiyama Y., Maesawa C., Ogasawara S., Terashima M., and Masuda T. 2003. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am. J. Pathol. 163: 1911.
2. Bachman K.E., Park B.H., Rhee I., Rajagopalan H., Herman J.G., Baylin S.B., Kinzler K.W., and Vogelstein B. 2003. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3: 89.
3. Bartolomei M.S. and Tilghman S.M. 1997. Genomic imprinting in mammals. Annu. Rev. Genet. 31: 493.
4. Bartolomei M.S., Zemel S., and Tilghman S.M. 1991. Parental imprinting of the mouse H19 gene. Nature 351: 153.
5. Beckwith J.B. 1998. Nephrogenic rests and the pathogenesis of Wilms tumor: Developmental and clinical considerations. Am. J. Med. Genet. 79: 268.
6. Beckwith J.B., Kiviat N.B., and Bonadio J.F. 1990. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr. Pathol. 10: 1.
7. Berenblum I. 1962. The epidemiology of cancer. In General pathology: Based on lectures delivered at the Sir William Dunn School of Pathology, University of Oxford (ed. H.B. Florey). W.B. Saunders, Philadelphia.
8. Caspary T., Cleary M.A., Perlman E.J., Zhang P., Elledge S.J., and Tilghman S.M. 1999. Oppositely imprinted genes p57 (Kip2) and IGF2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev. 13: 3115.
9. Cho M., Grabmaier K., Kitahori Y., Hiasa Y., Nakagawa Y., Uemura H., Hirao Y., Ohnishi T., Yoshikawa K., and Ooesterwijk E. 2000. Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines. Mol. Carcinog. 27: 184.
10. Christofori G., Naik P., and Hanahan D. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414.
11. Cui H., Horon I.L., Ohlsson R., Hamilton S.R., and Feinberg A.P. 1998. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4: 1276.
12. Cui H., Cruz-Correa M., Giardiello F.M., Hutcheon D.F., Kafonek D.R., Brandenburg S., Wu Y., He X., Powe N.R., and Feinberg A.P. 2003. Loss of IGF2 imprinting: A potential marker of colorectal cancer risk. Science 299: 1753.
13. DeBaun M.R. and Feinberg A.P. 2004. IGF2, H19, p57KIP2, and LIT1 and the Beckwith-Wiedemann syndrome. In Inborn errors of development: The molecular basis of clinical disorders of morphogenesis (ed. C.J. Epstein et al.). Oxford University Press, New York.
14. DeBaun M.R., Niemitz E.L., McNeil D.E., Brandenburg S.A., Lee M.P., and Feinberg A.P. 2002. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am. J. Hum. Genet. 70: 604.
15. DeChiara T.M., Robertson E.J., and Efstratiadis A. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64: 849.
16. Feinberg A.P. 1999. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction. Cancer Res. 59: 1743s.
17. Feinberg A.P. and Tycko B. 2004. The history of cancer epigenetics. Nat. Rev. Cancer 4: 143.
18. Feinberg A.P. and Vogelstein B. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89.
19. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Perez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., and Esteller M. 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37: 391.
20. Gama-Sosa M.A., Slagel V.A., Trewyn R.W., Oxenhandler R., Kuo K.C., Gehrke C.W., and Ehrlich M. 1983. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11: 6883.
21. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., and Jaenisch R. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300: 489.
22. Hao Y., Crenshaw T., Moulton T., Newcomb E., and Tycko B. 1993. Tumour-suppressor activity of H19 RNA. Nature 365: 764.
23. Hatada I., Ohashi H., Fukushima Y., Kaneko Y., Inoue M., Komoto Y., Okada A., Ohishi S., Nabetani A., Morisaki H., Nakayama M., Niikawa N., and Mukai T. 1996. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat. Genet. 14: 171.
24. Jones B.K., Levorse J.M., and Tilghman S.M. 1998. IGF2 imprinting does not require its own DNA methylation or H19 RNA. Genes Dev. 12: 2200.
25. Jones P.A. and Baylin S.B. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415.
26. Kang M.J., Park B.J., Byun D.S., Park J.I., Kim H.J., Park J.H., and Chi S.G. 2000. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clin. Cancer Res. 6: 1767.
27. Klein G. 2005. Epigenetics: Surveillance team against cancer. Nature 434: 150.
28. Knudson A.G., Jr. 1987. Prince Takamatsu memorial lecture. Rare cancers: Clues to genetic mechanisms. Princess Takamatsu Symp. 18: 221.
29. Lee M.P., Brandenburg S., Landes G.M., Adams M., Miller G., and Feinberg A.P. 1999a. Two novel genes in the center of the 11p15 imprinted domain escape genomic imprinting. Hum. Mol. Genet. 8: 683.
30. Lee M.P., DeBaun M.R., Mitsuya K., Galonek H.L., Brandenburg S., Oshimura M., and Feinberg A.P. 1999b. Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. Proc. Natl. Acad. Sci. 96: 5203.
31. Leighton P.A., Ingram R.S., Eggenschwiler J., Efstratiadis A., and Tilghman S.M. 1995. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375: 34.
32. Lund A.H. and van Lohuizen M. 2004. Epigenetics and cancer. Genes Dev. 18: 2315.
33. Mannens M., Hoovers J.M., Redeker E., Verjaal M., Feinberg A.P., Little P., Boavida M., Coad N., Steenman M., and Bliek J., et al. 1994. Parental imprinting of human chromosome region 11p15.3-pter involved in the Beckwith-Wiedemann syndrome and various human neoplasia. Eur. J. Hum. Genet. 2: 3.
34. Moulton T., Crenshaw T., Hao Y., Moosikasuwan J., Lin N., Dembitzer F., Hensle T., Weiss L., McMorrow L., and Loew T., et al. 1994. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat. Genet. 7: 440.
35. Nakanishi H., Suda T., Katoh M., Watanabe A., Igishi T., Kodani M., Matsumoto S., Nakamoto M., Shigeoka Y., Okabe T., Oshimura M., and Shimizu E. 2004. Loss of imprinting of PEG1/MEST in lung cancer cell lines. Oncol. Rep. 12: 1273.
36. Nishigaki M., Aoyagi K., Danjoh I., Fukaya M., Yanagihara K., Sakamoto H., Yoshida T., and Sasaki H. 2005. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 65: 2115.
37. Ogawa O., Eccles M.R., Szeto J., McNoe L.A., Yun K., Maw M.A., Smith P.J., and Reeve A.E. 1993. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362: 749.
38. Ohlsson R. 2004. Loss of IGF2 imprinting: Mechanisms and consequences. Novartis Found. Symp. 262: 108.
39. Ohlsson R., Nystrom A., Pfeifer-Ohlsson S., Tohonen V., Hedborg F., Schofield P., Flam F., and Ekstrom T.J. 1993. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat. Genet. 4: 94.
40. Ping A.J., Reeve A.E., Law D.J., Young M.R., Boehnke M., and Feinberg A.P. 1989. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am. J. Hum. Genet. 44: 720.
41. Rainier S., Johnson L.A., Dobry C.J., Ping A.J., Grundy P.E., and Feinberg A.P. 1993. Relaxation of imprinted genes in human cancer. Nature 362: 747.
42. Ravenel J.D., Broman K.W., Perlman E.J., Niemitz E.L., Jayawardena T.M., Bell D.W., Haber D.A., Uejima H., and Feinberg A.P. 2001. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J. Natl. Cancer Inst. 93: 1698.
43. Ripoche M.A., Kress C., Poirier F., and Dandolo L. 1997. Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. Genes Dev. 11: 1596.
44. Robertson K.D. 2005. DNA methylation and human disease. Nat. Rev. Genet. 6: 597.
45. Sakatani T., Kaneda A., Iacobuzio-Donahue C.A., Carter M.G., de Boom Witzel S., Okano H., Ko M.S., Ohlsson R., Longo D.L., and Feinberg A.P. 2005. Loss of imprinting of IGF2 alters intestinal maturation and tumorigenesis in mice. Science 307: 1976.
46. Sato N., Matsubayashi H., Abe T., Fukushima N., and Goggins M. 2005. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin. Cancer Res. 11: 4681.
47. Sellers W.R. and Loda M. 2002. The EZH2 polycomb transcriptional repressor: A marker or mover of metastatic prostate cancer? Cancer Cell 2: 349.
48. Sharifah N.A., Yun K., and McLay J. 1995. Insulin-like growth factor II gene expression by congenital mesoblastic nephroma. Diagn. Mol. Pathol. 4: 279.
49. Steenman M.J., Rainier S., Dobry C.J., Grundy P., Horon I.L., and Feinberg A.P. 1994. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 7: 433.
50. Waber P.G., Chen J., and Nisen P.D. 1993. Infrequency of ras, p53, WT1, or RB gene alterations in Wilms tumors. Cancer 72: 3732.
51. Weksberg R., Shen D.R., Fei Y.L., Song Q.L., and Squire J. 1993. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat. Genet. 5: 143.
52. Woodson K., Flood A., Green L., Tangrea J.A., Hanson J., Cash B., and Schoenfeld P. 2004. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J. Natl. Cancer Inst. 96: 407.
53. Yamada Y., Jackson-Grusby L., Linhart H., Meissner A., Eden A., Lin H., and Jaenisch R. 2005. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl. Acad. Sci. 102: 13580.
54. Yu Y., Xu F., Peng H., Fang X., Zhao S., Li Y., Cuevas B., Kuo W.L., Gray J.W., Siciliano M., Mills G.B., and Bast R.C., Jr. 1999. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. 96: 214.
55. Zhang Y. and Tycko B. 1992. Monoallelic expression of the human H19 gene. Nat. Genet. 1: 40.